Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the safety, efficacy and acceptability of HMR 3647 (20 percent fine granules 1g sachet) in children with infections

Next Previous
Trial Profile

Evaluation of the safety, efficacy and acceptability of HMR 3647 (20 percent fine granules 1g sachet) in children with infections

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jul 2009

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Telithromycin (Primary)
  • Indications Bacterial infections; Dental infections; Otorhinolaryngological infections; Respiratory tract infections; Skin infections
  • Focus Adverse reactions; Registrational
  • Sponsors Sanofi

Most Recent Events

  • 08 Apr 2009 Actual end date (May 2005) added as reported by ClinicalTrials.gov.
  • 15 Dec 2006 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top